Evidence map›Paper›PMID 30275714›Full record

ArticleOncoTargets and therapy2018

Lentivirus-mediated shRNA targeting

Qunjun Gao, Yuhan Liu, Haibiao Xie, Yucheng Zhong, Xinhui Liao, Hengji Zhan, Qun Zhou, Mengting Ding, Kang Yang, Aolin Li and 3 more

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Qunjun GaoKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangzhou 511436, China, caizhiming2000@163.com.
Yuhan LiuKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Haibiao XieKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Yucheng ZhongKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Xinhui LiaoDepartment of Urology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Hengji ZhanKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Qun ZhouKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Mengting DingKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Kang YangKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Aolin LiKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Yuchen LiuKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Hongbing MeiDepartment of Urology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China, liuyuchenmdcg@163.com, caizhiming2000@163.com.
Zhiming CaiKey Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangzhou 511436, China, caizhiming2000@163.com.
Shenzhen Second People's Hospital · CNSecond Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMATERIALS AND

methodsThe expression of

results

conclusionOur data suggest that

Indexed as

apoptosisbladder cancercell proliferationmigrationMUTYH

Identifiers

PMID30275714
PMCPMC6157993
OpenAlexW2891792958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.